בייאטה 5 מק"ג - Byetta 5 mcg
×××× ×× ×× × ×ספ×× ×©× ×××××× - Byetta
ש××× ×× !
×ת×ר××: 12.2.2017 ×תק××× ××××¢× ×× ×©×××ק ×תר××¤× ××פסק ×צ××ת×ת.
×ת×ר××: 12.2.2017 ×תק××× ××××¢× ×× ×©×××ק ×תר××¤× ××פסק ×צ××ת×ת.
×ק×ר: ××©×¨× ××ר×××ת - ××××¢×ת ×¢× ×פסקת ש×××ק תר×פ×ת
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ××× ×× ×× × ×ספ×× | ||||||
|---|---|---|---|---|---|---|
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | A10BJ Glucagon-like peptide-1 (GLP-1) analogues | |||||
| ×ר××× ×¤×¢×× (ATC5) | Â
| |||||
| צ×רת ××ª× | תת-×¢××¨× - S.C | |||||
| צ×רת ××× ×× | ת×××¡× ×××רק×, SOLUTION FOR INJECTION ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× | |||||
| ×ת×××× | BYETTA is indicated for treatment of type 2 diabetes mellitus in combination with:- metformin- sulphonylureas- thiazolidinediones- metformin and a sulphonylurea- metformin and a thiazolidinedionein adults who have not achieved adequate glycaemic control on maximally tolerated doses of theseoral therapies.BYETTA is also indicated as adjunctive therapy to basal insulin with or without metformin and/orpioglitazone in adults who have not achieved adequate glycaemic control with these agents.
| |||||
× ×ª×× × ×¡× [ ×צ×× ]
| ||||||
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
××× ×¢××× ×ר××¤× | |||||
| ×¢××× ×צר×× |  |
|---|
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| [ ×××××× 5 ×ק"×] ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | ASTRA ZENECA AB., SWEDEN |
| ×©× ××¢× ×ר×ש×× | ASTRA ZENECA (ISRAEL) LTD |
| ר×ש××× | ת×ר×× ××ש×: 04/2006. ר×ש××× ×ת×ר××: 01/2013 |
| ת×ר×× ×¢×××× ××ר×× | 12.2.2017 |